FDA Approves Imbruvica for Mantle Cell Lymphoma

Imbruvica for MCL

On November 13, 2013 the U.S. Food and Drug Administration (FDA) announced that it had approved a new drug called Imbruvica (ibrutinib) for the treatment of a rare type of non-Hodgkin lymphoma called mantle cell lymphoma (MCL).   Only about six percent of all Americans with non-Hodgkin lymphoma have this form.

MCL is quite aggressive.  Generally,  when it is discovered it has already spread to the bone marrow, lymph nodes and other organs.

The drug Imbruvica works by inhibiting an enzyme which is required by the cancer in order to grow and spread.

Imbruvica is intended for use in patients who have already tried at least one other treatment.

Two other drugs are also approved for the treatment of MCL:  Millenium Pharmaceutical’s Velcade, which was approved in 2006; and Summit’s Revlimid, which received approval earlier this year.

Imbruvica is the second drug to be designated as breakthrough therapy.  In July 2012, the passage of The Food and Drug Administration Safety and Innovation Act gave the agency the ability assign this designation at the request of the sponsor if preliminary data suggest that it may provide a significant improvement over existing treatments for very serious illnesses.

According to Dr. Richard Pazdur, director of the Office of Hematology and Oncology Products at the FDA’s Center for Drug Evaluation and Research, the FDA cooperated with the drug manufacturer to speed up the drug’s review and approval process because the FDA has a commitment to making new treatments available to those with rare diseases.  The accelerated approval process allows promising new drugs to get into the hands of seriously ill patients much sooner without them having to wait for the confirmatory clinical trials to be completed.

The FDA also gave Imbruvia priority review and orphan-product designation.  It received priority review because of its potential to provide a much safer or effective treatment for serious disease.  It received its orphan-product status because it is targeted towards treating a rare disease.

Imbruvica received expedited approval for the treatment of MCL based upon a study in which 111 patients were administered the drug every day until their disease worsened or they could no longer tolerate the side effects.  Almost 66 percent of the patients had cancer which either shrank or disappeared completely after being treated with the drug.  It has not been established yet whether the drug helped with survival or disease symptoms.

The most commonly reported side effects with Imbruvica were:  low platelet levels, decreased white blood cells, anemia, diarrhea, constipation, vomiting, upset stomach, decreased appetite,  musculoskeletal pain, fatigue, swelling, bruising, rash, shortness of breath, upper respiratory tract infection and abdominal pain.  Other side effects included bleeding, infections, kidney problems and the development of other cancers.

Inbruvica is being marketed for the treated of MCL by Pharmacyclics in Sunnyvale, CA and Janssen Biotech, Inc. in Raritan, NJ.

By Nancy Schimelpfening

Sources:

FDA Approves Imbruvica for Rare Blood Cancer – FDA

Developing Products for Rare Diseases and Conditions – FDA

Fast Track, Breakthrough Therapy, Accelerated Approval and Priority Review – FDA

RSS Guardian Express

  • Chris Brown Trial Delayed for Months April 24, 2014
    The assault charge trial for Chris Brown has been delayed for months because his bodyguard, who is a key witness in the singer’s case, was denied immunity. Bodyguard Christopher Hollosy said that he would not testify without immunity until he has finished appealing his own case. Immunity would allow Hollosy to testify without putting his […]
    Twanna Harps
  • Hawaii Announces Bruno Mars Day Again April 24, 2014
    Hawaii announced December 19 as Bruno Mars day, and then once again, Hawaii governor Neil Abercrombie declared Monday, April 21, 2014, as Bruno Mars Day. Usually when a state announces a holiday, it is a one-time event. The new day coincides with his three-day concert that was sold out in Honolulu. He is not the […]
    Heather Tillman
  • American Idol The Super Six Perform (Review & Videos) April 24, 2014
    American Idol tonight is down to the final six competitors of the season. The Super Six will perform twice, each one singing a country and a rock song, and then their fates will be in your hands, America! Vote on the one or ones you think did the best, or who you simply like the […]
    Douglas Cobb
  • Daniel Franzese of ‘Mean Girls’ Comes Out April 24, 2014
    In a heartwarming letter to his character, “Damien,” from the movie Mean Girls, Daniel Franzese is ready to come out of the closet. It has been close to 10 years since the release of the hit movie, and his letter is not only inspirational, but also sad in places. He tells “Damien” that he wished he had […]
    Kristi Cereska
  • Johnny Cueto Dominates for Cincinnati: Reds Report April 24, 2014
    For a team still trying to find their way Johnny Cueto is doing his part; dominating opposing hitters, making his case for the pitcher of the month in the National League in April and keeping the Cincinnati Reds afloat. Cueto is now 2-2 on the season with a 1.38 ERA and a WHIP of just 0.77. […]
    Mick Varner

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 630 other subscribers

Quantcast